

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 19-0365

File No.JB01603-K2-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Altmann et al.

Serial No.: 10/663,208 Group Art Unit: TBA

Filed: September 16, 2003 Examiner: TBA

For: NPC1L1 (NPC3) AND METHODS OF USE THEREOF

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This statement is made in compliance with 37 C.F.R. §1.56, 1.97 and 1.98. The Examiner's attention is directed to the documents listed on the accompanying form PTO-1449 and the enclosed copy of each listed document. Consideration of each cited document, and the return of an initialed, duplicate copy of the enclosed form PTO-1449 to indicate such consideration, are respectfully requested.

These documents may be relevant to examination of the application. Inclusion of a document is **not** an admission that the document is prior art with respect to the invention of the application and is **not** to be construed as an admission that anything in the document renders any claim of the application unpatentable.

Under 37 C.F.R. § 1.97(d), copies of the patent applications and publications cited in the accompanying PTO-1449 form are **not** provided because copies were provided in the parent of this application, U.S. Patent Application No. 10/621,758; filed July 17, 2003.

This statement is submitted before a first office action on the merits of the Application; accordingly, Applicants believe that no fee is required. If, however, any fees are due, the Office may charge such fees to Deposit Account No. 19-0365.

Date: OCt. 10, 2003

Respect only submitted

Thomas Triolo, Ph.D. Registration No. 48,001 Agent for Applicant(s)

Schering-Plough Corporation Patent Department; K-6-1, 1990 2000 Galloping Hill Road Kenilworth, NJ 07033 908-298-2347

Sheet 1 of 1

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE

ATTY. DOCKET NO.: JB01603-K2-US SERIAL NO.: 10/663,208

INFORMATION DISCLOSURE STATEMENT FOR PATENT

(Use several sheets if necessary)

APPLICANT: Altmann et al.

FILING DATE: September 16, 2003

GROUP: TO BE ASSIGNED

	•				September 16, 200.	3	LORE	<u> 1881GNI</u>	<u> </u>
			U.S. P	ATENT DOCUM	IENTS				
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CL	_ASS	SUB- CLASS	FILING APPRO	
	AA								
	AB								
			FOREIGN	PATENT DOC	UMENTS				
		DOCUMENT	DOCUMENT DATE COUNTRY CLASS		_ASS	SUB-	TRANS		
		NUMBER	0 4 07	14/150		4281	CLASS	YES	NO
	AC	WO 01/70974	Sept. 27,	WIPO		12N	15/12	Abstr.	
			2001					<u> </u>	
	AD	WO 01/57190	Aug. 9,	WIPO	C.	12N			
•			2001					ļ	
	AE								
-	AF								
<u></u>	ОТ	HER DOCUMEN	ITS (Includ	ding Author, Title	, Date, Pertine	nt Pa	iges, Et	c.)	
3	AG	Minhas, "Current Progress in Lipid Therapy" Br. J. Cardiology 10(1): 59-68 (2003)							
4	АН	Abstracts 1-79 from "The International Conference on Niemann-Pick Type C Disease"; May 29-							
		31, 2003.							
•	Al	Carstea et al.," Niemann-Pick C1 disease gene: homology to mediators of cholesterol							
		homeostasis" Science 277:228-231 (1997).							
	AJ	Polypeptide Sequence ABG22693 disclosed in WO 01/75067 A2							
•	AK	Genbank Sequence Disclosure; Accession No. AF192522.							
€.	AL	Genbank Sequence Disclosure; Accession No. AF002020.							
	АМ	Davies et al., " Evidence for a Niemann-pick C (NPC) gene family: identification and							
		characterization of NPC1L1" Genomics 65(2): 137-145 (2000).							
	AN	The state of the s							
		71(1-2): 175-181 (2000).							
	AO Genbank Sequence Disclosure, Accession No. AK078947.								
	AP	- 1/00 001							
		expression cloning and its role in cholesterol absorption." Biochim. Biophys. ACTA 1580: 77-93							
		(2002).							
	AQ	DeNinno et al., "Steroidal glycoside cholesterol absorption inhibitors. " J. Med. Chem. 40(16):2547-2554 (1997).							

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.